Apotex markets generic Plavix
Just a week after Apotex Corp. announced that it was going to market the first generic version of clopidogrel bisulfate (Plavix) 75-mg tablets, the innovator companies-Sanofi-Aventis and Bristol-Myers Squibb-filed a request for an injunction in the U.S. District Court for the Southern District of New York, in an attempt to block Apotex from selling clopidogrel.
Apotex markets generic Plavix
Just a week after Apotex Corp. announced that it was going to market the first generic version of clopidogrel bisulfate (Plavix) 75-mg tablets, the innovator companies-Sanofi-Aventis and Bristol-Myers Squibb-filed a request for an injunction in the U.S. District Court for the Southern District of New York, in an attempt to block Apotex from selling clopidogrel. The brand-name companies claim, among other things, that they are likely to win a pending patent case. Canadian-based Apotex will have 180 days of market exclusivity for clopidogrel. The drug is used to prevent heart attacks and strokes. Clopidogrel sales in 2005 were more than $6 billion, and, as of June 2006, 2006 sales were $3.77 billion. The FDA approved Apotex' application for clopidogrel in January. Meanwhile, the Justice Department is looking into whether Sanofi-Aventis and Bristol-Myers Squibb tried to enter into a patent settlement with Apotex in order to delay the generic launch until 2011.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
